The post Ripple CTO Emeritus Reacts to XRP Price, Shiba Inu Prints 666% Spike in Futures, Dogecoin Erases Zero — U.Today Crypto Digest appeared on BitcoinEthereumNewsThe post Ripple CTO Emeritus Reacts to XRP Price, Shiba Inu Prints 666% Spike in Futures, Dogecoin Erases Zero — U.Today Crypto Digest appeared on BitcoinEthereumNews

Ripple CTO Emeritus Reacts to XRP Price, Shiba Inu Prints 666% Spike in Futures, Dogecoin Erases Zero — U.Today Crypto Digest

For feedback or concerns regarding this content, please contact us at [email protected]

Ex-Ripple CTO shares candid truth about XRP and crypto market

Ripple CTO Emeritus David Schwartz shared a candid response on X about the XRP price with respect to the broader crypto market.

An X user had asked whether the price of XRP was making him feel depressed. Schwartz admitted that he felt “a little” down about it but clarified that his feelings were not limited to XRP alone: “The whole crypto market makes me sad sometimes. Anyone know why?”

The former Ripple CTO, one of the original architects of the XRP Ledger, frequently interacts with the crypto community on social media. Thus, his response on X seems to reflect broader market sentiment rather than XRP specifically.

Ripple CTO Emeritus Reacts to XRP Price, Shiba Inu Prints 666% Spike in Futures, Dogecoin Erases Zero — U.Today Crypto Digest

Key Crypto Bill Could Pass in July, Industry Lobbyist Says

The crypto market has seen continued sell-off since October, when nearly $20 billion in leveraged bets were liquidated.

Altcoins, including XRP, are struggling within the crypto market, and even more so since the Oct. 10 event. According to CryptoQuant, 38% of altcoins are near all-time lows, with the recent drop worse than the post-FTX period. 

Shiba Inu prints mark of the beast in 666% futures flow spike

Bitcoin spiked very unexpectedly, but unfortunately it did not bring any fresh funds to alternative cryptocurrencies like Shiba Inu.

Shiba Inu is garnering attention on derivatives markets once more following an unusual surge in futures activity that caused flows to rise sharply. Recent data shows that SHIB experienced an extreme short-term increase in futures flow of about 666%, which indicates a sudden wave of speculative positioning around the asset.  

The magnitude of the spike indicates that traders are quickly taking positions as volatility starts to increase, even though the number itself is more symbolic than significant.

SHIB is currently trading at about $0.0000056, indicating a slight intraday recovery following a protracted downtrend that has dominated the market for several months. The larger chart still shows a bearish structure in spite of this slight rebound. 

The price is still trading below the major moving averages, such as the 50- and 200-day lines, which are still pointing lower and support the general downward trend.

DOGE removed a zero for eight hours, but will it return?

Dogecoin made a breakthrough attempt, but it was not enough to shift the trend.

After a brief spike lifted the meme asset above the psychologically significant $0.10 level, Dogecoin gave traders a brief moment of excitement. DOGE was able to remove a zero from its price structure for about eight hours, trading in five-digit territory before rapidly falling back below that level.

The broader technical picture still indicates that Dogecoin is still stuck in a wider downtrend, even though the move raised hopes for a possible recovery. As of this writing, DOGE is trading close to $0.096, just below the crucial resistance level of $0.10 that recently rejected the rally.

After a spike in buying pressure drove the price out of the $0.09 area, a short-term breakout took place. Additionally, volume increased during the move, indicating that genuine market participation, rather than thin liquidity, was the driving force behind the rally.

The comeback, though, was only temporary. Sellers reclaimed control and pushed the asset back down once the price hit the $0.10 range. This behavior emphasizes how significant the resistance cluster that has developed there is.

Source: https://u.today/ripple-cto-emeritus-reacts-to-xrp-price-shiba-inu-prints-666-spike-in-futures-dogecoin-erases-zero

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3666
$1.3666$1.3666
+0.74%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09